FEELM and RELX international Launch First Whole Chain Recycling Scheme for Disposable Vapes in the UK
22.5.2023 14:53:00 EEST | Business Wire | Press release
World leading closed system solution provider FEELM has joined forces with leading vaping brand RELX to launch the UK vape industry’s first whole-chain recycling scheme for single use devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005354/en/
FEELM Cooperates with RELX for the first industrial whole chain recycling scheme
The initiative aims to address the growing concerns surrounding single use products being thrown away by consumers and the environmental impact caused by them ending up in landfill.
It follows estimates from independent non-profit organization Material Focus that 1.3 million single use vape devices are discarded each week in the UK which, taken over a year, contain enough lithium to power 1,200 electric vehicles.
Also, based on market research by Opinium, around 168 million disposable vapes are bought annually in the UK, with half of those being thrown out with regular waste rather than being disposed of in a waste electricals recycling bin or being returned to the retailer.
This new initiative will see FEELM, the flagship brand of inhalation tech company SMOORE, team up with leading single use vape provider RELX to implement sustainability strategies which will benefit both their business partners, customers and the wider community.
The initiative involves a household collection system, a transparent recycling process and retailer partnerships to make it as easy as possible for consumers to participate.
Consumers can send their used vapes to FEELM either through pre-paid postage labels downloaded online or by visiting one of the retail partners. The household collection system simplifies the recycling process, making it more accessible to a broader audience.
To encourage consumers to participate in the recycling scheme, FEELM plans to introduce an incentive mechanism that boosts consumer engagement. For every ten used devices sent back, RELX provides a brand new RELX Magic Go disposable vape with FEELM Max technology. The FEELM Max boasts impressive performance and sets a new TPD-compliant industry benchmark, offering 800 puffs with its 2 ML capacity.
By fostering a recycling mindset and strengthening education around recycling, the company aims to create a more environmentally conscious community that actively participates in sustainable practices.
By offering a comprehensive and convenient recycling method, FEELM and RELX hope to raise the environmental awareness of end users, inspire trust in the recycling system and encourage consumers to play their part in helping protect the environment.
Delivering the Social Responsibility
Commenting on the recycling scheme, Johnny Zhang, Assistant President at FEELM said: “We firmly believe that disposables have a critical part to play in helping the UK achieve its smokefree aspirations. The industry needs to do much more in the environmental department, but it is starting to make headway.
“Our green innovation program is well underway, but we are now ramping it up significantly to ensure we don’t just help protect adult smokers’ lives but also the planet too.
“This commitment to making recycling more accessible demonstrates our dedication to corporate social responsibility and environmental sustainability. As this initiative gains traction, we hope it will serve as a model for other industries looking to implement eco-friendly practices and engage adult customers in their sustainability efforts.”
Chris Aikens, Senior External Affairs Manager for Europe at RELX International, said: “We are pleased to be working with SMOORE on this project which highlights our commitment to the long-term sustainability of disposable devices. These products provide a useful tool to enable adult smokers to make the switch from combustible cigarettes and their full potential needs to be recognised. This recycling scheme will benefit both the planet and adult consumers.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005354/en/
Contact information
Ruiqi Wang
ruiqi.wang@smooretech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
